Association between sarcopenia and respiratory function in elderly orthopedic outpatients

Yoshihito Tomita, PhDab,* Satoshi Mizukami, PhDbc, Takayuki Nishimura, PhDbcd, Kazuhiko Arima, MD, PhDb, Yasuyo Abe, MD, PhDb, Mitsuoh Kanagae, PhDbcd, Kiyoshi Aoyagi, MD, PhDb,

Abstract
The relationship between sarcopenia and respiratory function has not been investigated in elderly Japanese orthopedic outpatients. This study aimed to assess the relationship between sarcopenia and respiratory function in elderly orthopedic outpatients in Japan. Elderly outpatients (N = 102; aged ≥65 years) with orthopedic diseases were enrolled in the study. Muscle mass was measured using the bioelectrical impedance analysis. Grip strength and walking speed were measured (2 trials). The respiratory function (e.g., percent vital capacity [VC] and percent forced expiratory volume in 1 second) was also measured. The association between sarcopenia and respiratory function was assessed using logistic regression analysis, adjusting for sex, comorbidities, and smoking status.

The mean ages for men and women were 77.7 ± 8.3 and 76.5 ± 6.8 years, respectively, and the overall prevalence of sarcopenia was 25.5% (30.0% and 24.4% in men and women, respectively). The study demonstrated that low respiratory function, which was represented by decreased percent VC, was associated with sarcopenia in outpatients visiting an orthopedic department (odds ratio, 1.73; 95% confidence interval: 1.02–2.97).

Sarcopenia was significantly associated with a lower percentage of VC in orthopedic outpatients after adjustment for sex, comorbidity, and smoking. Further studies are needed to determine the causality.

Abbreviations: AMI = appendicular muscle mass index, BMI = body mass index, FEV1 = forced expiratory volume in 1 second, FVC = female, FVC = forced vital capacity, M = male, SD = standard deviation, VC = vital capacity.

Keywords: cross-sectional study, elderly, Japanese, orthopedic outpatient, respiratory function, sarcopenia
aged >65 years. Moreover, the peak expiratory flow rate was reported to be associated with sarcopenia in Japanese community-dwelling older adults. However, the relationship between sarcopenia and respiratory function has not been investigated in elderly Japanese orthopedic outpatients. Thus, the purpose of this study was to assess the relationship between sarcopenia and respiratory function in elderly orthopedic outpatients in Japan.

2. Methods

Participants were recruited from patients with orthopedic diseases who visited the Nishi-Ishaya Hospital and enrolled voluntarily in this observational study. Written consent forms were available in Japanese to ensure a comprehensive understanding, and each participant provided written informed consent. This study was approved by the Ethics Committee for Human Use of Nagasaki University on June 20, 2016 (project registration no. 16060293).

The participants included 109 elderly outpatients aged ≥65 years with orthopedic diseases. We carried out a power analysis that showed that the sample size was sufficient for our statistical analyses (G*Power ver. 3.1: test family [t2 test], statistical test [goodness of fit test: contingency tables], effect size = 0.40, alpha error = 0.05, 1-beta error = 0.80, total sample size = 81). G*Power was designed as a general stand-alone power analysis program for statistical tests commonly used in social and behavioral research. All participants had sufficient cognitive function to complete the questionnaire and were asked if they had any comorbidities (heart, lung disease, stroke, or diabetes mellitus). In addition, information on current smoking status (yes/no) was collected. Diagnosis of musculoskeletal disorders (osteoarthritis, rheumatoid arthritis, fracture and others) was collected. The sites of pain (shoulder, elbow, wrist, finger, hip, knee, ankle, foot, upper back pain, mid back and low back) were collected, but the severity of pain was not assessed. Height (m) and weight (kg) were measured with participants wearing light clothing and without shoes and body mass index (BMI) was calculated as weight divided by height squared (kg/m²).

The participants were classified as having sarcopenia based on muscle mass, muscle strength, and physical performance. The classification was established on the recommendations of the Asian Working Group for Sarcopenia. These recommendations defined sarcopenia as age >60 years, a low handgrip strength (<28 kg and 18 kg in men and women, respectively) and/or slower walking speed (<1.0 m/s), low appendicular muscle mass index (AMI; <7.0 and 5.7 kg/m² in men and women, respectively). Participants without low muscle mass, strength, or low physical performance were classified as normal.

Muscle mass was measured by bioelectrical impedance analysis using an InBody 430 (InBody Japan Inc., Tokyo, Japan). The bioelectrical impedance analysis method requires participants to step onto a platform and remain in the standing position for approximately 30 seconds. Appendicular skeletal muscle mass was calculated as the sum of the muscle masses of the 4 limbs. The absolute appendicular muscle mass was converted to an AMI, which was calculated by dividing the absolute appendicular muscle mass by height in meters squared (kg/m²).

The grip strength of the dominant hand was measured using a Jamar hydraulic hand dynamometer (Jafayette Instrument Company, Inc., Jafayette, IN). The best performance of the 2 trials was accepted as the result.

The walking speed was calculated as the time required for participants to walk a 10-m course at their usual pace (usual walking speed; average of 2 trials).

An electronic spirometer (Microspiro HI-205, Nihonkohden Inc., Tokyo, Japan) was used to measure vital capacity (VC), forced expiratory volume in 1 second (FEV1), and percent FEV1 (FEV1/VC). The participants were seated comfortably in a chair. For the measurement of VC, participants were asked to breathe spontaneously several times, exhale until the point of maximal expiration, inhale to the point of maximal inspiration, and exhale again. For the measurement of FVC, they were asked to inhale to the point of maximal inspiration and exhale as quickly as possible over the following 6 seconds. The effort during the measurement was evaluated using a flow–volume curve. The VC was measured first, followed by the FVC. After several practice attempts, measurements were performed once for each participant. However, when a participant appeared to exert submaximal effort, measurements were repeated until maximal effort was achieved. The best values for each parameter were used in the analysis.

2.1. Statistical analysis

We used the Shapiro–Wilk test for the normality test. Comparisons of variables between the sarcopenia and the normal group were performed using Student t test for continuous variables or Fisher exact test for categorical variables. The association between sarcopenia and respiratory function was assessed using logistic regression analysis, adjusting for sex, comorbidities, and smoking status. The Hosmer–Lemeshow test was used to evaluate the difference between the observed and predicted prevalence in the multivariate logistic regression analysis. Odds ratios and 95% confidence intervals were calculated. Statistical significance was set at P < .05. All statistical analyses were performed using IBM SPSS Statistics version 27 (IBM Corp., Armonk, NY).

3. Results

Participants with missing values (n = 6) for any variables and pacemaker implantation (n = 1) were excluded from the analysis, leaving the remaining (n = 102) for the final data analysis (Fig. 1). The prevalence of musculoskeletal disorders of the participants was osteoarthritis (n = 47, 46.1%), rheumatoid arthritis (n = 4, 3.9%), fracture (n = 44, 43.1%), and others (n = 7, 6.9%). All participants experienced at least 1 musculoskeletal pain. The sites of pain were shoulder (n = 71, 69.6%), elbow (n = 13, 12.7%), wrist (n = 12, 11.8%), finger (n = 11, 10.8%), hip (n = 17, 16.7%), knee (n = 52, 51.0%), ankle (n = 16, 15.7%), foot (n = 11, 10.8%), upper back pain (n = 24.5, 25.0%), mid back pain (n = 13, 12.7%), and low back pain (n = 67, 65.7%).

The study flow is shown in Figure 2. Table 1 shows the characteristics of male and female participants. The mean ages of men and women were 77.7 ± 8.3 and 76.5 ± 6.8 years, respectively. Women had significantly lower AMI, grip strength, VC, and FEV1 than men (P < .001). The mean percent VC was greater in women than in men (P = .016). The number of participants who were current smokers was higher among men (P < .001).

The overall prevalence of sarcopenia in the present study was 25.5% (30.0% and 24.4% in men and women, respectively; Table 2).

Table 3 shows the comparison of variables between the sarcopenia and normal groups. In all participants, the sarcopenia group had lower BMI, AMI, grip strength, usual walking speed, VC, percent VC, and FEV1 (all P < .05), whereas percent FEV1, comorbidity, and smoking did not differ significantly. Men and women with sarcopenia had significantly lower BMI (P = .002 and P < .001 in men and women, respectively), AMI (P = .006 and P < .001 in men and women, respectively), grip strength (P = .003 and P < .001 in men and women, respectively), VC (P = .005 and P = .013 in men and women, respectively), and FEV1 (P = .037 and P = .021 in men and women, respectively) compared to normal. Higher age (P = .032) and lower percent VC (P = .014) were associated with sarcopenia in men. Women with sarcopenia had significantly slower walking speed (P < .001).

After adjustment for sex, comorbidity, and smoking, the sarcopenia group had a significantly lower percentage of VC in...
orthopedic outpatients (Table 4). The percent FEV1 was not significantly associated with sarcopenia.

4. Discussion

4.1. Prevalence of sarcopenia

In the present study, the prevalence of sarcopenia was 30.0% and 24.4% in men and women, respectively, a higher rate than that reported in previous reports of community-dwelling elderly persons.[15–17] In addition, all the participants experienced at least 1 musculoskeletal pain. Pain was a significant predictor of sarcopenia transition over a 9-year period,[18] which may reflect avoidance of physical activity due to fear of pain.[6] Sarcopenia is suspected to be a serious problem among elderly orthopedic outpatients.

4.2. Sarcopenia and low pulmonary function

We demonstrate that low pulmonary function, after adjustment for sex, comorbidity, and smoking, represented by decreased percent VC, is associated with sarcopenia based on the consensus of the Asian Working Group for Sarcopenia[14] in outpatients visiting an orthopedics department. Respiratory muscles, especially inspiratory ones, are significantly related to limb muscle strength and skeletal muscle mass.[19] As aging progresses, skeletal muscle mass decreases, and respiratory muscle mass may also decrease,[20] which is consistent with our results.

4.3. Sarcopenia and percent FEV1

In the present investigation, percent FEV1 (FEV1/VC) was not associated with sarcopenia, unlike FEV1 and VC, and these findings are consistent with previous ones.[11,20] VC usually represents lung volume, and FEV1, the expiratory flow rate; therefore, VC and FEV1 can be reduced in participants with low muscle mass, because they may have weakened abilities to inflate and deflate their lungs.[21] Here, both VC and FEV1 were lower in the sarcopenia than in the normal group. However, percent FEV1 (FEV1/VC) represents upper airway obstruction and may remain invariant, regardless of muscle mass,[20,22] which may in part be the reason for the lack of association between percent FEV1 and sarcopenia.

4.4. Sarcopenia, comorbidity, and smoking

The prevalence of sarcopenia is increased in patients with chronic heart failure.[23] Hemiparetic stroke leads to muscle abnormalities with a combination of denervation, disuse, remodeling, and spasticity, which may account for a complex pattern of phenotype shift and atrophy.[24,25] Muscle strength loss is associated with diabetes and smoking.[26] Thus, a
logistic regression analysis adjusting for these variables was performed.

4.5. Limitations

The present study had several limitations. First, because the study was cross-sectional in nature, causal relationships between sarcopenia and low respiratory function were not possible. Hence, a longitudinal study is required to determine the causality. Second, the findings were obtained from elderly Japanese orthopedic outpatients. Therefore, the results cannot be extrapolated to other ethnicities. Third, patients may have difficulty judging the severity of comorbidities, consequently, the severity was not evaluated. Moreover, we did not collect information regarding the medications and the severity of pain. Thus, these limitations might have contributed to the underestimation of the associations. Finally, there was a possibility of selection bias due to the single-hospital study.

5. Conclusions

The overall prevalence of sarcopenia in the present study was 25.5% (30.0% and 24.4% in men and women, respectively), a higher rate than that reported in previous studies of community-dwelling elderly persons. Sarcopenia was significantly associated with a lower percentage of VC in orthopedic outpatients after adjustment for sex, comorbidity, and smoking. Pulmonary function tests, which are regularly measured in

Table 1

Characteristics of the participants (N = 102).

| Variable                        | All (N = 102) | Men (n = 20) | Women (n = 82) | P value |
|---------------------------------|--------------|-------------|----------------|---------|
|                                | Mean SD      | Mean SD     | Mean SD        |         |
| Age, y                          | 76.8 ± 7.1   | 77.7 ± 8.3  | 76.5 ± 6.8     | .512    |
| Body mass index, kg/m²          | 23.5 ± 3.8   | 22.5 ± 2.9  | 23.8 ± 4.0     | .175    |
| AMI, kg/m²                      | 6.1 ± 0.9    | 7.0 ± 0.7   | 5.9 ± 0.8      | <.001*  |
| Grip strength, kg               | 22.0 ± 6.4   | 29.9 ± 7.5  | 20.0 ± 4.4     | <.001*  |
| Walking speed, m/s              | 1.1 ± 0.2    | 1.1 ± 0.2   | 1.1 ± 0.2      | .398    |
| VC, L                           | 2.5 ± 0.6    | 3.0 ± 0.7   | 2.3 ± 0.4      | .001*   |
| Percent VC, %                   | 107.0 ± 20.8 | 97.0 ± 19.3 | 109.4 ± 20.6   | .016*   |
| FEV₁, L                         | 1.77 ± 0.4   | 2.1 ± 0.5   | 1.7 ± 0.4      | .001*   |
| Percent FEV₁, %                 | 72.0 ± 9.4   | 71.6 ± 18.6 | 72.0 ± 8.7     | .879    |

| Variable                        | Number %    | Number %    | Number %    |         |
|---------------------------------|-------------|-------------|-------------|---------|
| Comorbidity,† yes               | 78 (76.5%)  | 12 (60.0%)  | 66 (84.6%)  | .076    |
| Heart disease, yes              | 17 (16.7%)  | 3 (15.0%)   | 14 (17.1%)  | .823    |
| Lung disease, yes               | 14 (13.7%)  | 5 (25.0%)   | 9 (11.0%)   | .102    |
| Stroke, yes                     | 7 (6.9%)    | 2 (10.0%)   | 5 (6.1%)    | .536    |
| Diabetes mellitus, yes          | 11 (10.8%)  | 2 (10.0%)   | 9 (11.0%)   | .900    |
| Smoking, yes                    | 19 (18.6%)  | 15 (75.0%)  | 4 (4.9%)    | <.001*  |

Student t test for continuous variables; Fisher exact test for categorical variables. Men vs women.

AMI = appendicular muscle mass index, FEV₁ = forced expiratory volume in 1 second, SD = standard deviation, VC = vital capacity.

*P value <.05.

†Heart, lung disease, stroke, or diabetes mellitus.

Table 2

Prevalence of sarcopenia (N = 102).

| Variable                        | All (N = 102) | Men (n = 20) | Women (n = 82) | P value |
|---------------------------------|--------------|-------------|----------------|---------|
|                                | Number %     | Number %    | Number %       |         |
| Low AMI, kg/m²                  | 42 (41.2%)   | 7 (35.0%)   | 35 (42.7%)     |         |
| Low walking speed               | 38 (37.3%)   | 7 (35.0%)   | 31 (37.8%)     |         |
| Low grip strength               | 29 (28.4%)   | 7 (35.0%)   | 22 (26.8%)     |         |
| Sarcopenia                      | 26 (25.5%)   | 6 (30.0%)   | 20 (24.4%)     |         |

Table 3

Comparison of variables between the sarcopenia and the normal group (N = 102).

| Variable                        | Sarcopenia | Normal | P value |
|---------------------------------|------------|--------|---------|
|                                | Number     | Number |         |
| Age, y                          | 78.9 ± 8.0 | 76.1 ± 6.6 | .082    |
| Body mass index, kg/m²          | 21.2 ± 2.4 | 24.3 ± 3.9 | <.001*  |
| AMI, kg/m²                      | 5.4 ± 0.6  | 6.4 ± 0.9 | <.001*  |
| Grip strength, kg               | 18.6 ± 4.6 | 24.0 ± 6.5 | <.001*  |
| Walking speed, m/s              | 0.9 ± 0.2  | 1.1 ± 0.2 | <.001*  |
| VC, L                           | 2.2 ± 0.4  | 2.6 ± 0.6 | <.003*  |
| Percent VC, %                   | 98.3 ± 19.1| 109.9 ± 20.7| .014    |
| FEV₁, L                         | 1.8 ± 0.4  | 1.8 ± 0.4 | .013*   |
| Percent FEV₁, %                 | 72.3 ± 8.9 | 71.8 ± 9.2 | .802    |
| Comorbidity,† yes               | 22 (84.6%) | 56 (73.7%) | .257    |
| Smoking, yes                    | 6 (23.1%)  | 13 (17.1%) | .500    |

Men

| Age, y                          | 83.7 ± 8.5 | 75.1 ± 7.1 | .032*   |
| Body mass index, kg/m²          | 19.7 ± 3.0 | 23.7 ± 1.9 | .002*   |
| AMI, kg/m²                      | 6.2 ± 0.6  | 7.3 ± 0.3  | .006*   |
| Grip strength, kg               | 23.5 ± 5.5 | 33.7 ± 0.2 | .003*   |
| Walking speed, m/s              | 1.0 ± 0.2  | 1.1 ± 0.2  | .334    |
| VC, L                           | 2.4 ± 0.4  | 3.2 ± 0.6  | .005*   |
| Percent VC, %                   | 81.6 ± 16.6| 103.6 ± 16.7| .014*   |
| FEV₁, L                         | 1.8 ± 0.3  | 2.2 ± 0.5  | .037*   |
| Percent FEV₁, %                 | 77.5 ± 10.2| 69.1 ± 10.0| .913    |
| Comorbidity,† yes               | 4 (66.7%)  | 8 (57.1%)  | .545    |
| Smoking, yes                    | 5 (83.3%)  | 10 (71.4%) | .517    |

Women

| Age, y                          | 77.4 ± 7.4 | 78.3 ± 6.6 | .515    |
| Body mass index, kg/m²          | 21.6 ± 2.1 | 24.5 ± 4.2 | <.001*  |
| AMI, kg/m²                      | 5.2 ± 0.4  | 6.2 ± 0.8  | <.001*  |
| Grip strength, kg               | 17.1 ± 3.1 | 21.8 ± 4.2 | <.001*  |
| Walking speed, m/s              | 0.9 ± 0.2  | 1.2 ± 0.2  | <.001*  |
| VC, L                           | 2.1 ± 0.4  | 2.4 ± 0.4  | .013*   |
| Percent VC, %                   | 103.3 ± 17.1| 111.3 ± 21.4| .133    |
| FEV₁, L                         | 1.5 ± 0.4  | 1.7 ± 0.3  | .021*   |
| Percent FEV₁, %                 | 70.8 ± 8.1 | 72.4 ± 9.0 | .474    |
| Comorbidity,† yes               | 18 (90%)   | 48 (77.4%) | .184    |
| Smoking, yes                    | 1 (5)      | 3 (4.8%)   | .681    |

Mean ± standard deviation, number (%). Student t test for continuous variables; Fisher exact test for categorical variables.

AMI = appendicular muscle mass index, FEV₁ = forced expiratory volume in 1 second, VC = vital capacity.

*P value <.05.

†Heart, lung disease, stroke, or diabetes mellitus.
Table 4

| Variables          | Unit   | Odds ratio (95% confidence interval) |
|--------------------|--------|------------------------------------|
| Percent VC         | −20.8%*| 1.73 (1.02–2.97)†                   |
| Adjusted factors   |        |                                    |
| Smoking            | Yes    | 0.69 (0.15–3.27)                   |
| Sex                | Women  | 1.07 (0.20–5.71)                   |
| Comorbidity‡       | Yes    | 1.87 (0.53–6.55)                   |
| Smoking            | Yes    | 0.78 (0.15–4.19)                   |
| Adjusted factors   |        |                                    |
| Smoking            | Yes    | 0.83 (0.18–3.97)                   |
| Comorbidity‡       | Yes    | 2.15 (0.64–7.25)                   |
| Smoking            | Yes    | 0.69 (0.15–3.27)                   |

Logistic regression analysis. FEV1 = forced expiratory volume in 1 second, VC = vital capacity.

*1 standard deviation.
†P value <.05.
‡Heart, lung disease, stroke, or diabetes mellitus.

the hospital and before surgery, may be useful predictors of sarcopenia.

Acknowledgments

The authors thank all the participants. The authors wish to express their gratitude to the medical staff and colleagues at Nishi-Isahaya Hospital for supporting this study through their kind cooperation.

Author contributions

YT, SM, KA, TN, YA, MK, and KAo designed the study. YT collected and analyzed the data and drafted the manuscript. KAo supervised and assisted with data collection and analysis, and manuscript preparation. YT, SM, KA, TN, YA, MK, and KAo advised on the study design and data analysis and edited the manuscript. All authors read and approved the final manuscript.

References

[1] Rosenberg IH. Summary comments. Am J Clin Nutr. 1989;50:1231–3.
[2] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in older people. Age Ageing. 2010;39:412–23.
[3] Yeung SSY, Reijnierse EM, Pham VK, et al. Sarcopenia and its association with falls and fractures in older adults: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10:485–500.
[4] Woo J. Sarcopenia. Clin Geriatr Med. 2017;33:305–14.
[5] Scott D, Blizzard L, Fell J, et al. Prospective study of self-reported pain, radiographic osteoarthritis, sarcopenia progression, and falls risk in community-dwelling older adults. Arthritis Care Res (Hoboken). 2012;64:30–7.
[6] Vlaeyen JWS, Linton SJ. Fear-avoidance and its consequences for chronic musculoskeletal pain: a state of the art. Pain. 2000;85:317–32.
[7] Kitamura A, Seino S, Abe T, et al. Sarcopenia: prevalence, associated factors, and the risk of mortality and disability in Japanese older adults. J Cachexia Sarcopenia Muscle. 2021;12:30–8.
[8] Sakai Y, Matsu H, Ito S, et al. Sarcopenia in elderly patients with chronic low back pain. Osteoporos Sarcopenia. 2017;3:195–200.
[9] Torii M, Hashimoto M, Hana A, et al. Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol. 2019;29:589–95.
[10] Greising SM, Mantilla CB, Gorman BA, et al. Diaphragm muscle sarcopenia in aging mice. Exp Gerontol. 2013;48:881–7.
[11] Moon JH, Kong MH, Kim HJ. Implication of sarcopenia and sarcopenic obesity on lung function in healthy elderly: using Korean national health and nutrition examination survey. J Korean Med Sci. 2015;30:1682–8.
[12] Kera T, Kawai H, Hirano H, et al. Relationships among peak expiratory flow rate, body composition, physical function, and sarcopenia in community-dwelling older adults. Aging Clin Exp Res. 2018;30:331–40.
[13] Faul F, Erdfelder E, Lang A-G, et al. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–91.
[14] Chen L-K, Woo J, Assantachai P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21:300–307.e2.
[15] Yuki A, Ando F, Otsuka R, et al. Epidemiology of sarcopenia in elderly Japanese. J Phys Fit Sports Med. 2015;4:111–5.
[16] Matsumoto H, Tanimura C, Tanishima S, et al. Sarcopenia is a risk factor for falling in independently living Japanese older adults: a 2-year prospective cohort study of the GAINA study. Geriatr Gerontol Int. 2017;17:2124–30.
[17] Uemura K, Makizako H, Lee S, et al. The impact of sarcopenia on incident homebound status among community-dwelling older adults: a prospective cohort study. Matuntas. 2018;113:26–31.
[18] Murphy RA, Ip EH, Zhang Q, et al. Transition to sarcopenia and determinants of transitions in older adults: a population-based study. J Gerontol A Biol Sci Med Sci. 2014;69:751–8.
[19] Shim H, Kim DK, Seo KM, et al. Relation between respiratory muscle strength and skeletal muscle mass and hand grip strength in the healthy elderly. Ann Rehabil Med. 2017;41:686–92.
[20] Park CH, Yi Y, Do JG, et al. Relationship between skeletal muscle mass and lung function in Korean adults without clinically apparent lung disease. Medicine (Baltimore). 2018;97:e12281.
[21] Choe EK, Lee Y, Kang HY, et al. Association between CT-measured abdominal skeletal muscle mass and pulmonary function. J Clin Med. 2019;8:667–78.
[22] Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–68.
[23] Springer J, Springer JL, Anker SD. Muscle wasting and sarcopenia in heart failure and beyond: update 2017. ESC Heart Fail. 2017;4:492–8.
[24] Scherbakov N, von Haehling S, Anker SD, et al. Stroke induced sarcopenia: muscle wasting and disability after stroke. Int J Cardiol. 2013;170:89–94.
[25] Carda S, Cisari C, Invernizzi M. Sarcopenia or muscle modifications in neurologic diseases: a lexical or pathophysiological difference? Eur J Neurol. 2013;20:89–94.
[26] Stenholm S, Taina K, Rantanen T, et al. Long-term determinants of muscle strength decline: prospective evidence from the 22-year mini-Finland follow-up survey. J Am Geriatr Soc. 2012;60:77–85.